It has been postulated that anti-inflammatory properties of SGLT2 inhibitors with cardiometabolic risk factors including T2DM can play a crucial role in improving survival and quality of life along with reducing the number of HF-related outcomes and hospital admissions [49]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.